|
Patient
|
Age
|
Sex
|
Duration of LN (years)
|
LN class
|
Previous medications and outcome
|
Baseline TPU (g/24 h)
|
Baseline prednisone (mg/d)
|
Baseline creatine (μmol/L)
|
Outcome of iguratimod treatment
|
Follow-up time (weeks)
|
Follow-up
|
|---|
|
1
|
30
|
F
|
13
|
IV → III§
|
Cyc → Cs* (CR → F)
|
5.17
|
15
|
43
|
PR
|
36
|
Discontinue (relapse)
|
| | | | |
Cyc → LEF* (CR → F)
| | | | | | |
| | | | |
RTX (NR)
| | | | | | |
|
2
|
45
|
F
|
12
|
III
|
Pulse steroids (CR → F)
|
1.34
|
5
|
39
|
CR
|
84
|
Follow-up
|
| | | | |
Cyc (PR → F)
| | | | | | |
| | | | |
MMF (NR)
| | | | | | |
| | | | |
TAC (NR)
| | | | | | |
|
3
|
18
|
F
|
6
|
III + V
|
MMF (PR → F)
|
2.33
|
10
|
75.5
|
PR
|
132
|
Follow-up
|
| | | | |
TAC (PR → F)
| | | | | | |
|
4
|
49
|
F
|
7
|
III + V
|
Cyc → MMF* (CR → F)
|
4.92
|
0
|
63
|
PR
|
12
|
Discontinue (SAE)
|
| | | | |
TAC (NR)
| | | | | | |
|
5
|
55
|
F
|
18
|
III + V
|
CYC (CR → AE)
|
3.33
|
10
|
77
|
CR
|
132
|
Follow-up
|
| | | | |
LEF (NR)
| | | | | | |
| | | | |
Cyc (NR)
| | | | | | |
| | | | |
MMF (PR → F)
| | | | | | |
| | | | |
TAC (PR → F)
| | | | | | |
|
6
|
29
|
F
|
6
|
IV + V
|
TAC (NR)
|
3.48
|
0
|
35
|
CR
|
118
|
Follow-up
|
| | | | |
MMF (PR → F)
| | | | | | |
|
7
|
30
|
F
|
23
|
IV
|
Cyc (CR → F)
|
6.01
|
15
|
72
|
PR
|
24
|
Discontinue (relapse)
|
| | | | |
MMF (PR → F)
| | | | | | |
| | | | |
Cs (NR)
| | | | | | |
| | | | |
LEF (NR)
| | | | | | |
|
8
|
31
|
F
|
5
|
III + VI → IV + V§
|
Cyc → MMF* (PR → F)
|
1.96
|
10
|
52
|
NR
|
28
|
NR
|
| | | | |
TAC (NR)
| | | | | | |
|
9
|
32
|
F
|
5
|
III + V
|
Cyc (NR)
|
6.01
|
35
|
155
|
CR
|
36
|
Discontinue (extra-renal relapse)
|
| | | | |
MMF (NR)
| | | | | | |
| | | | |
Sirolimius (NR)
| | | | | | |
|
10
|
26
|
F
|
4
|
III → V§
|
Cyc (NR)
|
13.79
|
0
|
105
|
Lost
|
4
|
Lost to follow-up
|
| | | | |
Cs (NR)
| | | | | | |
| | | | |
TAC (NR)
| | | | | | |
|
11
|
46
|
M
|
6
|
III
|
Cyc (PR → F)
|
6.24
|
10
|
72
|
PR
|
16
|
Follow-up
|
| | | | |
MMF (PR → F)
| | | | | | |
|
12
|
19
|
F
|
2
|
IV + V
|
LEF (NR)
|
1.32
|
0
|
40.2
|
PR
|
36
|
Discontinue (relapse)
|
| | | | |
MMF (PR → F)
| | | | | | |
|
13
|
24
|
M
|
10
|
III + V
|
Cyc (NR)
|
2.21
|
0
|
81
|
PR
|
32
|
Follow-up
|
| | | | |
Cs (NR)
| | | | | | |
| | | | |
MMF (NR)
| | | | | | |
| | | | |
TAC (NR)
| | | | | | |
| | | | |
LEF + Tripterygium (NR)
| | | | | | |
| | | | |
Cyc (NR)
| | | | | | |
|
14
|
34
|
F
|
6
|
IV
|
Cyc → LEF* (CR → F)
|
2.57
|
10
|
43
|
CR
|
36
|
Follow-up
|
| | | | |
Cs (CR → F)
| | | | | | |
| | | | |
MMF (NR)
| | | | | | |
| | | | |
TAC (NR)
| | | | | | |
| | | | |
AZA (NR)
| | | | | | |
- TPU total proteinuria, Cyc cyclophosphamide, AZA azathioprine, Cs cyclosporine, LEF leflunomide, RTX rituximab, MMF mycophenolate mofetil, TAC tacrolimus, CR complete remission, PR partial remission, NR no response, SAE severe adverse event
- *Represents cyclophosphamide (typically 6 months) in sequence with other immunosuppressive agents. In this situation, the patients usually achieved PR or CR when the cyclophosphamide treatment ended
- §Patients agreed to repeated renal biopsies before iguratimod treatment
